公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges | Chow L.Q.M.; Barlesi F.; Bertino E.M.; Van Den Bent M.J.; Wakelee H.A.; Wen P.Y.; Chiu C.-H.; Orlov S.; Chiari R.; Majem M.; McKeage M.; CHONG-JEN YU ; Garrido P.; Hurtado F.K.; Arratia P.C.; Song Y.; Branle F.; Shi M.; Kim D.-W. | Clinical Cancer Research | 19 | 14 | |
2014 | Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer | Pallaud C.; Reck M.; Juhasz E.; Szima B.; CHONG-JEN YU ; Burdaeva O.; Orlov S.; Hilton M.; Archer V.; Mok T. | Lung Cancer | 18 | 16 | |
2014 | A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: Results of the phase II randomized ABIGAIL study (BO21015) | Mok T.; Gorbunova V.; Juhasz E.; Szima B.; Burdaeva O.; Orlov S.; CHONG-JEN YU ; Archer V.; Hilton M.; Delmar P.; Pallaud C.; Reck M. | Journal of Thoracic Oncology | 46 | 44 | |
2020 | Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC | Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU ; Tsai C.-M.; Cobo M.; McKeage M.; Su W.-C.; Mok T.; Scagliotti G.V.; Spigel D.R.; Viraswami-Appanna K.; Chen Z.; Passos V.Q.; Shaw A.T. | Journal of Thoracic Oncology | 26 | 19 | |
2017 | First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study | Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU ; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr | The Lancet | 901 | 771 | |
2018 | Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study | Gambacorti-Passerini C.; Orlov S.; Zhang L.; Braiteh F.; Huang H.; Esaki T.; Horibe K.; Ahn J.-S.; Beck J.T.; Edenfield W.J.; Shi Y.; Taylor M.; Tamura K.; Van Tine B.A.; SHANG-JU WU ; Paolini J.; Selaru P.; Kim T.M. | American Journal of Hematology | 70 | 63 | |
2010 | A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer | Tan E.-H.; Ramlau R.; Pluzanska A.; Kuo H.-P.; Reck M.; Milanowski J.; Au J.S.-K.; Felip E.; PAN-CHYR YANG ; Damyanov D.; Orlov S.; Akimov M.; Delmar P.; Essioux L.; Hillenbach C.; Klughammer B.; McLoughlin P.; Baselga J. | Annals of Oncology | 35 | 32 | |
2020 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study | Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG ; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. | The Lancet Oncology | 297 | 252 |